Biomarkers in inflammatory bowel disease

Edith Pérez De Arce*, Roció Sedano, Rodrigo Quera

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Biomarkers in inflammatory bowel disease are an essential tool in clinical practice. They allow a non-invasive evaluation of patients and thus guide decision-making at different stages of the disease, including diagnostic suspicion, severity assessment, relapse prediction, and treatment response. Although biomarkers in blood such as erythrocyte sedimentation rate and C-reactive protein, are the most commonly used biomarkers, because their low cost and accessibility, they lack specificity. Currently, fecal biomarkers offer greater reliability, applicability, and specificity. Fecal calprotectin is the most commonly used marker. This review discusses the advantages and disadvantages of biomarkers in inflammatory bowel disease, as well as their clinical applications and new biomarkers currently under research.

Original languageEnglish
Pages (from-to)362-370
Number of pages9
JournalRevista Medica de Chile
Issue number3
StatePublished - Mar 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 Sociedad Medica de Santiago. All rights reserved.


  • Biomarkers
  • Colitis, ulcerative
  • Crohn disease
  • Inflammatory bowel diseases


Dive into the research topics of 'Biomarkers in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this